Brief: Bachem Says Enters Strategic Collaboration With Lilly To Manufacture Oligonucleotide-Based Drug Substances

BACHEM HOLDING AG

26/04/2022 05:23

April 26 (Reuters) - Bachem Holding AG  BANB.S :
    * BACHEM ENTERS STRATEGIC COLLABORATION WITH LILLY TO
MANUFACTURE 
OLIGONUCLEOTIDE-BASED DRUG SUBSTANCES
    * BACHEM SAYS CO WILL PROVIDE APPROPRIATE ENGINEERING
INFRASTRUCTURE, EXPERTISE TO IMPLEMENT LILLY’S NOVEL
OLIGONUCLEOTIDE MANUFACTURING TECHNOLOGY
    * BACHEM SAYS LILLY COMMITS TO PLACING MANUFACTURING
PROJECTS WITH
BACHEM OVER THE NEXT SEVEN YEARS WITH  INCREASING MATERIAL
SUPPLY DEMANDS


Further company coverage:  BANB.S 

 ((reuters.briefs@thomsonreuters.com;))